Our study demonstrates that BAY-876, a GLUT1 inhibitor, effectively induces disulfidoptosis by limiting glucose uptake and disrupting NADPH regeneration, significantly reducing tumor growth in SLC7A11-high xenograft models. Here, SLC7A11 is linked to neoplasm.